A U.K. national commission published recommendations to update how AI-enabled healthcare products are regulated, arguing the Medicines and Healthcare products Regulatory Agency’s oversight powers need to extend beyond single approvals to life-cycle monitoring. The report frames the issue around AI systems’ ability to iterate, change behavior across settings, and depend on data, workflows, and organizations. The blueprint adds to a growing regulatory focus on governance, performance monitoring, and real-world reliability rather than treating AI devices as static products. For developers and clinical adopters, the recommendations signal that documentation and post-market controls may become as important as initial clearance, especially for rapidly adapting algorithms.